Transparency notification received from SAFFELBERG INVESTMENTS NV

Article 14 of the Law of 2 May 2007 on disclosure of major holdings

Liège, Belgium - 05 July 2022 - Regulated information - Hyloris Pharmaceuticals SA (Euronext Brussels: HYL) a specialty biopharma company committed to addressing unmet medical needs through reinventing existing medications, today announces that it has received a transparency notification dated 29 June 2022 indicating that the shareholdings held by Saffelberg Investments NV have crossed below the minimum threshold of 3%.

The notification dated 29 June 2022 contains the following information:

- Reason for the notification:
  - Downward crossing of the lowest threshold
  - Acquisition or disposal of voting securities or voting rights
- Notification by: A person that notifies alone
- Person subject to the notification requirement: Saffelberg Investments NV
- Transaction date: 22 June 2022
- Threshold that is crossed: 3%
- Denominator: 28.000.374

The notification can be consulted on the website of Hyloris Pharmaceuticals, under the heading “New Denominator and Transparency Notification”.

About Hyloris Pharmaceuticals
Hyloris is a specialty biopharma company focused on innovating, reinventing, and optimizing existing medications to address important healthcare needs and deliver relevant improvements for patients, healthcare professionals and payors. Hyloris has built a broad, patented portfolio of 14 reformulated and repurposed value-added medicines that have the potential to offer significant advantages over available alternatives. Outside of its core strategic focus, the Company also has 4 high barrier generic products in development. Two products are currently in initial phases of commercialization with partners: Sotalol IV for the treatment of atrial fibrillation, and Maxigesic® IV, a non-opioid post-operative pain treatment. The Company’s development strategy primarily focuses on the FDA’s 505(b)2 regulatory pathway, which is specifically designed for pharmaceuticals for which safety and efficacy of the molecule have already been established. This pathway can reduce the clinical burden required to bring a product to market, and significantly shorten the development timelines and reduce costs and risks. Hyloris is based in Liège, Belgium. For more information, visit www.hyloris.com and follow-us on LinkedIn.

For more information contact:
Hyloris Pharmaceuticals, Investors and Media
investorrelations@hyloris.com

Disclaimer and forward-looking statements

Hyloris means “high yield, lower risk”, which relates to the 505(b)(2) regulatory pathway for product approval on which the Issuer focuses, but in no way relates or applies to an investment in the Shares. Certain statements in this press release are “forward-looking statements.” These forward-looking statements can be identified using forward-looking terminology, including the words "believes", "estimates," "anticipates", "expects", "intends", "may", "will", "plans", "continue", "ongoing", "potential", "predict", "project", "target", "seek" or "should", and include statements the Company makes concerning the intended results of its strategy. These statements relate to future events or the Company’s future financial performance and involve known and unknown risks, uncertainties, and other factors, many of which are beyond the Company’s control, that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.